Golden Era of Pharma - Eli Lilly Stock Price Prediction 2024 2025 2030 2040 2050

Eli Lilly Stock Price Prediction 2024 2025 2030 2040 2050 – Today we are going to discuss about Eli Lilly and Company (LLY), located in the Indianapolis, Indiana US, is a prominent American pharmaceutical firm.

If you are considering investing in Eli Lilly stock for the long term, it is important to analyze its potential growth and performance. Our Eli Lilly’s Stock Forecast is based on a deep technical analysis and past performance of Eli Lilly’s Stock to help you make an informed decision.

To begin with, it is essential to understand Eli Lilly’s business model and financial data. Once you have a clear understanding of the company’s operations and financial strength, you can determine whether Eli Lilly’s stock is a good buy or not.

Our Eli Lilly’s Stock Price Forecast covers the stock’s potential growth and performance for the years 2024, 2025, 2030, and 2040 to help you make an informed investment decision.

Contents

1 About Eli Lilly
2 Financial Overview of Eli Lilly
3 Stock Price Chart of Eli Lilly and Company
4 Eli Lilly Revenue Details
- 4.1 Eli Lilly Revenue Chart
5 What are the PROs and CONs of investing in Eli Lilly?
- 5.1 PROs of investing in Eli Lilly
- 5.2 CONs of investing in Eli Lilly
6 Eli Lilly Stock Price Prediction 2024 to 2050
7 Eli Lilly Balance Sheet
8 Video Related to Eli Lilly Stock Price Prediction
9 Conclusion
10 Eli Lilly Stock Price Prediction FAQs
11 Disclaimer

About Eli Lilly

Eli Lilly and Company, also known as Lilly, is a prominent American pharmaceutical firm with its headquarters in Indianapolis, Indiana. Established by Colonel Eli Lilly in 1876, the company’s primary goal was to develop top-quality medications that address genuine medical needs.

Lilly boasts a wide array of products across various therapeutic areas including endocrinology, oncology, cardiology, and neurology. Some of their well-known offerings encompass insulin for diabetes management, popular antidepressants like Prozac, cancer treatments such as Alimta, and the erectile dysfunction medication Cialis.

With a rich history of pioneering advances in the pharmaceutical sector, Lilly continues to hold a leading position in the realms of drug innovation and healthcare solutions.

For Diabetes

The company provides Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 to manage diabetes.

For Obesity

They also offer Jardiance, Mounjaro, and Trulicity for individuals with type 2 diabetes, as well as Zepbound for treating obesity.

For Oncology

It offers cancer treatment medications such as Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Others

In addition, the company provides –

Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19;
Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis;
Omvoh for ulcerative colitis;
Cymbalta for depression, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain;
Ebglyss for severe atopic dermatitis; and
Emgality for the prevention of migraines and episodic cluster headaches.

Also Read – When will Spotify reach $500? Spotify Stock Forecast 2025 2030 2040 2050 2060

Financial Overview of Eli Lilly

Stock Name	Eli Lilly and Company
Stock Exchange	NYSE
Industry	Drug Manufacturers – General
Sector	Healthcare
Market Cap	842.05B
Revenue (ttm)	35.93B
Net Income (ttm)	6.14B
Shares Out	950.41M
EPS (ttm)	6.79
PE Ratio	130.48
Forward PE	59.45
Dividend	$5.20 (0.59%)
Ex-Dividend Date	May 15, 2024

Volume	2,735,417
Open	893.00
Previous Close	891.46
Day’s Range	870.13 – 905.45
52-Week Range	434.34 – 905.45
Beta	0.36
Analysts	Strong Buy
Price Target	798.15 (-9.91%)
Earnings Date	Aug 6, 2024
Official Website	Eli Lilly and Company

Stock Price Chart of Eli Lilly and Company

Eli Lilly Stock Price Chart — @Courtesy Yahoo Finance

Eli Lilly Revenue Details

Eli Lilly Revenue Chart

What are the PROs and CONs of investing in Eli Lilly?

PROs of investing in Eli Lilly	CONs of investing in Eli Lilly
Innovative Drug Pipeline – Lilly’s drug pipeline shows promise for driving future growth.	Valuation Concerns i.e High Valuation – The stock’s significant gains may make it seem overpriced, potentially limiting future returns.
Blockbuster Products – The company has multiple successful products in the market.	Fluctuating Sales – Decreasing demand for COVID treatments and patent expirations may have an impact on sales.
Financial Stability – With its established status as a pharmaceutical giant, Lilly has the financial resources to support its operations.	Regulatory Risks – Pharmaceutical companies are subject to strict regulations that can influence drug approvals and sales.
Growth Potential – Positioned well for growth, the company is developing new drugs.	Market Competition – The pharmaceutical sector experiences intense competition, which can affect market share and pricing.
Historical Performance – Over the past few years, Lilly’s stock has demonstrated significant gains.	Patent Losses – Key drugs losing patent protection can result in competition from generic alternatives and a decline in revenue.
Diverse Portfolio – The company’s diverse portfolio of products across various therapeutic areas reduces reliance on any single product.	Drug Development Risks – The process of developing drugs is expensive and uncertain, with no guarantee of success.
Research and Development – Ongoing investment in research and development may result in breakthroughs and new patents.	Economic Vulnerability – The healthcare sector may be susceptible to economic downturns, affecting consumer spending on healthcare.
Dividend Payouts – Lilly’s track record includes consistent dividend payments, offering an income source for investors.	Legal Challenges – Litigation risks associated with drug safety or patents can have financial implications.

Eli Lilly Stock Price Prediction 2024 to 2050

Year	Min Target Price	Max Target Price
2024	$550	$ 928.45
2025	$823	$1198
2026	$921	$1490
2027	$1021	$1645
2028	$1105	$1899
2029	$1211	$2097
2030	$1312	$2610
2035	$2350	$5650
2040	$3840	$9875
2050	$9345	$14120

Eli Lilly Stock Price Prediction 2024

Here are details for Eli Lilly Stock Forecast 2024 or Eli Lilly Stock Target 2024

– Min Target Price – $550
– Max Target Price – $928.45

Eli Lilly Stock Price Prediction 2025

Here are details for Eli Lilly Stock Forecast 2025 or Eli Lilly Stock Target 2025

– Min Target Price – $823
– Max Target Price – $1198

Eli Lilly Stock Price Prediction 2026

Here are details for Eli Lilly Stock Forecast 2026 or Eli Lilly Stock Target 2026

– Min Target Price – $921
– Max Target Price – $1490

Eli Lilly Stock Price Prediction 2027

Here are details for Eli Lilly Stock Forecast 2027 or Eli Lilly Stock Target 2027

– Min Target Price – $1021
– Max Target Price – $1645

Eli Lilly Stock Price Prediction 2028

Here are details for Eli Lilly Stock Forecast 2028 or Eli Lilly Stock Target 2028

– Min Target Price – $1105
– Max Target Price – $1899

Eli Lilly Stock Price Prediction 2029

Here are details for Eli Lilly Stock Forecast 2029 or Eli Lilly Stock Target 2029

– Min Target Price – $1211
– Max Target Price – $2097

Eli Lilly Stock Price Prediction 2030

Here are details for Eli Lilly Stock Forecast 2030 or Eli Lilly Stock Target 2030

– Min Target Price – $1312
– Max Target Price – $2610

Eli Lilly Stock Price Prediction 2035

Here are details for Eli Lilly Stock Forecast 2035 or Eli Lilly Stock Target 2035

– Min Target Price – $2350
– Max Target Price – $5650

Eli Lilly Stock Price Prediction 2040

Here are details for Eli Lilly Stock Forecast 2040 or Eli Lilly Stock Target 2040

– Min Target Price – $3840
– Max Target Price – $9875

Eli Lilly Stock Price Prediction 2050

Here are details for Eli Lilly Stock Forecast 2050 or Eli Lilly Stock Target 2050

– Min Target Price – $9345
– Max Target Price – $14120

Eli Lilly Balance Sheet

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2,819	2,067	3,819	3,657	2,338
Short-Term Investments	109.1	144.8	90.1	24.2	101
Cash & Cash Equivalents	2,928	2,212	3,909	3,681	2,439
Cash Growth	32.37%	-43.41%	6.17%	50.97%	-67.09%
Receivables	11,336	8,559	8,127	6,929	5,542
Inventory	5,773	4,310	3,886	3,980	3,191
Other Current Assets	5,690	2,954	2,531	2,872	2,539
Total Current Assets	25,727	18,035	18,452	17,462	13,710
Property, Plant & Equipment	12,914	10,144	8,985	8,682	7,873
Long-Term Investments	3,052	2,902	3,213	2,967	1,962
Goodwill and Intangibles	11,846	11,280	11,584	11,217	10,297
Other Long-Term Assets	10,467	7,130	6,572	6,306	5,444
Total Long-Term Assets	38,279	31,455	30,354	29,171	25,577
Total Assets	64,006	49,490	48,806	46,633	39,286
Accounts Payable	2,599	1,931	1,671	1,607	1,405
Current Debt	6,905	1,501	1,538	8.7	1,499
Other Current Liabilities	17,790	13,707	11,844	10,866	8,871
Total Current Liabilities	27,293	17,138	15,053	12,482	11,775
Long-Term Debt	18,321	14,738	15,346	16,587	13,818
Other Long-Term Liabilities	7,529	6,839	9,252	11,740	10,994
Total Long-Term Liabilities	25,849	21,576	24,599	28,326	24,812
Total Liabilities	53,143	38,714	39,651	40,808	36,587
Total Debt	25,225	16,239	16,885	16,595	15,317
Debt Growth	55.34%	-3.83%	1.74%	8.34%	48.73%
Retained Earnings	10,312	10,043	8,959	7,830	4,920
Comprehensive Income	-4,327	-3,844.6	-4,343.1	-6,496.4	-6,523.6
Shareholders’ Equity	10,772	10,650	8,979	5,642	2,607
Net Cash / Debt	-22,297.6	-14,026.8	-12,976.1	-12,914	-12,878.7
Net Cash Per Share	-24.69	-15.51	-14.23	-14.15	-13.76
Working Capital	-1,566.2	896.3	3,400	4,981	1,934
Book Value Per Share	11.97	11.81	9.90	6.22	2.80

Video Related to Eli Lilly Stock Price Prediction

Conclusion

We hope you will like the information given by us. We have covered almost all the information (Financial data, Pros and Cons of investing, Competitors etc) along with forecast, which is necessary to evaluate any company fundamentally as well as technically. And if you want more information related to stock prediction. You can read our article and stay with us so that you can know the prediction of more stocks in the future.

Also, do your due diligence and comment to us, whether you will invest in this stock or not. Till then Happy Investing.

Eli Lilly Stock Price Prediction FAQs

What will Eli Lilly stock be worth in 5 years?

In accordance with the most recent long-term projections, it is anticipated that the price of Eli Lilly stock will reach –

– Min Target Price – $1211
– Max Target Price – $2097

Is Eli Lilly a buy sell or hold?

Eli Lilly & Co has received a consensus rating of Strong Buy, based on assessments from 19 Wall Street analysts over the past 3 months. The rating is derived from 16 buy ratings and 3 hold ratings, with no sell ratings reported. The average 12-month price target for Eli Lilly & Co is $878.88, according to the analysts’ evaluations.
Is Eli Lilly overvalued?

Is Eli Lilly profitable?

Eli Lilly’s gross profit experienced a significant increase, surging from $19 billion in 2020 to $27 billion in 2023. This growth coincided with an expansion of the gross profit margin from 77.7% to 79.2% over the same period. Additionally, Eli Lilly witnessed an increase in its operating margin, rising from 28.9% in 2020 to 31.6% in 2023, and further to 32.9% for the trailing twelve-month period.

Is Eli Lilly a good dividend stock?

In consideration of dividend growth, the company presently offers an annualized dividend of $2.96, reflecting a 14.7% increase from the previous year. Over the past five years, Eli Lilly has elevated its dividend on a year-over-year basis four times, resulting in an average annual growth rate of 6.02%.

Is Eli Lilly a good long term stock?

Eli Lilly has consistently demonstrated robust financial performance, characterized by substantial revenue and earnings growth, particularly evident in the first quarter of 2024. This commendable financial showing is likely to positively impact investor confidence.

What is the dividend for Eli Lilly in 2024?

In the realm of Health Technology stocks, it is not uncommon for companies to refrain from issuing dividends. However, Eli Lilly and Company stands apart by offering dividends to its shareholders. For the quarter ending in June 2024, the company declared a dividend of $1.3, reflecting a dividend yield of 0.63%.

Who is CEO of Eli Lilly?

Dave Ricks serves as the chairman and CEO of Eli Lilly and Company.

What is Eli Lilly debt ratio?

In the first quarter of 2024, Eli Lilly and Co’s debt to equity ratio stood at 2.05. A high debt to equity ratio typically indicates that a company has pursued aggressive financing for its expansion through debt. This approach can lead to fluctuations in earnings due to increased interest expenses.

Who are the competitors of Eli Lilly?

Below are the competitors of Eli Lilly –

Pfizer Inc
Merck & Co., Inc
Novartis AG
Johnson & Johnson
Bristol Myers Squibb
AbbVie Inc.
AstraZeneca PLC

Top 10 Pharma Companies in the US by Market Capitalization

Top 10 Pharma Companies in the US by Market Capitalization are as –

Eli Lilly and Co
Johnson & Johnson
Merck & Co Inc
AbbVie Inc
Pfizer Inc
Amgen Inc
Bristol-Myers Squibb Co
Vertex Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Gilead Sciences Inc

Who owns Eil Lilly Company or Who are the shareholders of Eil Lilly Company

Follwing are the main shareholders of Eil Lilly Company –

Holder	# of Shares	Type	% Holding	Value
Lilly Endowment Inc	97,583,810	Insider	10.27%	86,992,063,263
Vanguard	64,667,551	Institution	6.80%	57,648,535,014
Vanguard Index Funds	59,718,699	Institution	6.28%	53,236,831,411
iShares	32,094,123	Institution	3.38%	28,610,626,890
SPDR	27,284,848	Institution	2.87%	24,323,350,598
Theofanis Kolokotrones	21,254,190	Institution	2.24%	18,947,260,217
Fidelity Concord Street Trust	12,666,193	Institution	1.33%	11,291,404,412
Vanguard Chester Fund	12,377,711	Institution	1.30%	11,034,234,248
Fidelity Contrafund	7,984,709	Institution	0.84%	7,118,048,685
Growth Fund of Ameria	7,855,413	Institution	0.83%	7,002,786,473

Disclaimer

This article contains information that may be useful for those interested in the stock market. However, it is important to note that we do not provide recommendations to buy or sell any stocks. Investing in the stock market carries inherent risks, so it is crucial to conduct thorough research on any company before making any investment decisions.